Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Camlin Fine Sciences Ltd Capital/Financing Update 2021

May 16, 2021

59255_rns_2021-05-16_7537fee7-df41-4280-8315-824d40641b33.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Date: May 16, 2021

==> picture [100 x 31] intentionally omitted <==

To, To,
BSE Limited, The Manager,
25, P. J. Towers, Listing Department,
Dalal Street, National Stock Exchange of India Ltd.,
Mumbai – 400 001 Exchange Plaza, Bandra Kurla Complex,
**Ref:**Company Scrip Code: 532834 Bandra (East), Mumbai‐ 400051
**Ref:Symbol:**CAMLINFINE

Sub: Disclosure of events or information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Our intimation dated May 16, 2021 regarding strategic investment in AlgalR NutraPharms Private Limited.

Dear Sir/Madam,

Further to our intimation dated May 16, 2021 regarding strategic investment in AlgalR NutraPharms Private Limited, we further wish to inform you that the total cost of the said acquisition shall not exceed INR 6.50 Crores.

We request you to kindly take the above on record.

Thanking you, For Camlin Fine Sciences Limited Mandar Godbole Company Secretary & General Manager ‐ Legal

==> picture [426 x 57] intentionally omitted <==